CT-314 Multicenter Long-Term Follow Up of Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
Chenyu Lin(Duke University), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Isabell S. Badell(Hospital de Sant Pau), Olga Frankfurt, Patrick J. Stiff(Loyola University Medical Center), David Valcárcel(Vall d'Hebron Hospital Universitari), Corey Cutler(Harvard University), William Y.K. Huang(Singapore General Hospital), Claudio G. Brunstein(Hotel Dieu Hospital), Rabi Hanna(Cleveland Clinic), Joseph P. McGuirk(University of Kansas Medical Center), Caroline A. Lindemans(University Medical Center Utrecht), Guillermo Sanz(Instituto de Salud Carlos III), Ron Ram(Tel Aviv University), Amy K. Keating(Boston Children's Hospital), Joanne Kurtzberg(Duke University), Madan Jagasia(Vanderbilt University Medical Center), Ronit Simantov(Pfizer (United States)), Andrew R. Rezvani(Stanford Blood Center), Liang Piu Koh(National University Cancer Institute, Singapore), Richard T. Maziarz(Oregon Health & Science University), Aurélie Schwarzbach(Gamida Cell (Israel)), Suhag Parikh(Emory University), Juliana Folloni Fernandes(European Organisation for Rare Diseases), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k